S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations

The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon-gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients with a history of malignancy and viral hepatitis.

Authors

Institutions

Publication Details

Journal
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Published
2026-02-01
DOI
https://doi.org/10.1111/ddg.16001
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations

Brit Häcker, Ralph von Kiedrowski, Arno Köllner, Sandra Philipp et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Psoriasis: Treatment and Pathogenesis
article

S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations

Brit Häcker, Ralph von Kiedrowski, Arno Köllner, Sandra Philipp, Antonia Pennitz, W. Boehncke, Christoph Zeyen, Prof. Alexander Nast, Tom Schaberg, Thomas Rosenbach, Andreas Altenburg, H.M. Ockenfels, Joachim Klaus, Hilte Geerdes‐Fenge, Uwe Willuhn, Michael Sebastian, Martin Schlaeger, Gerhard Schmid‐Ott, Markus Cornberg, Thomas Richter, Peter Härle, Frank Bachmann, Michaela Köhm, Matthias Augustin, Karisa Thölken, Ulrich Mrowietz
article en

Abstract

The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon-gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients with a history of malignancy and viral hepatitis.

JDDG Journal der Deutschen Dermatologischen GesellschaftVol. 24(2)
Goethe University Frankfurt (DE), University of Geneva (CH), Universität Hamburg (DE), University Hospital Augsburg (DE), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), Sana Kliniken Duisburg (DE), Klinikum Hanau (DE), Städtisches Klinikum Dessau (DE), Hôpital Beau-Séjour (CH), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), University Medical Center Hamburg-Eppendorf (DE), Klinikum Oldenburg (DE), University Hospital Schleswig-Holstein (DE), Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer (DE), Psoriasis Association (GB), University Hospital Frankfurt (DE), Hospital Selayang (MY), Waldkrankenhaus Protestant Hospital (DE), Mahlo (Germany) (DE), BG Klinikum Duisburg (DE), German Central Institute for Social Issues (DE), Center for Rheumatology (US), Hochschule der Polizei des Landes Brandenburg (DE), University of Rostock (DE), University of Lübeck (DE)
Good health and well-being
Openalex Percentile: Top 65%
Psoriasis: Treatment and Pathogenesis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.